BrainsWay Ltd. (BWAY)

Market Cap	173.14M
Revenue (ttm)	38.63M
Net Income (ttm)	1.50M
Shares Out	33.10M
EPS (ttm)	0.04
PE Ratio	115.43
Forward PE	51.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,532
Open	8.86
Previous Close	8.96
Day's Range	8.82 - 9.35
52-Week Range	4.61 - 10.98
Beta	0.37
Analysts	Strong Buy
Price Target	13.17 (+42.53%)
Earnings Date	Nov 12, 2024

About BWAY

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 17, 2019
• Employees: 134
• Stock Exchange: NASDAQ
• Ticker Symbol: BWAY
• Website: https://www.brainsway.com

Financial Performance

In 2023, BrainsWay's revenue was $31.79 million, an increase of 16.96% compared to the previous year's $27.18 million. Losses were -$4.20 million, -68.56% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price forecast is $13.17, which is an increase of 42.53% from the latest price.

Price Target

$13.17

(42.53% upside)

Analyst Consensus: Strong Buy